Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.44 USD | +1.95% | +0.76% | +41.04% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Low profitability weakens the company.
- With an expected P/E ratio at 93.27 and 63.82 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.04% | 3.58B | C+ | ||
-17.86% | 8.35B | B+ | ||
-8.06% | 2.47B | - | ||
-38.71% | 2.46B | B- | ||
-7.96% | 2.36B | B- | ||
-15.98% | 1.78B | C- | ||
-19.73% | 1.53B | A- | ||
-40.78% | 1.21B | C+ | ||
+8.32% | 1.12B | B+ | ||
-10.43% | 1.09B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RDNT Stock
- Ratings RadNet, Inc.